Management Team

Andrew D. Goldberg, MD, was appointed Chief Executive Officer of Achieve Life Sciences in April 2026. Dr. Goldberg is a physician, healthcare investor, and governance leader who has spent his career at the intersection of clinical medicine and commercial execution. Most recently, he served as a Portfolio Manager at Marshall Wace and previously as a Partner at Vivo Capital, a healthcare-focused investment firm. Earlier in his career, he was a consultant at McKinsey & Company in Silicon Valley, advising pharmaceutical, biotechnology, and medical device companies. He has served as a board director or observer at 19 life sciences companies, including Tarsus Pharmaceuticals (Nasdaq: TARS) through FDA approval and the national launch and commercialization of XDEMVY, Veradermics (NYSE: MANE) through its successful IPO, Inquis Medical through FDA approval and commercialization of the Aventus thrombectomy system, Elektrofi through its $900M acquisition by Halozyme Therapeutics (Nasdaq: HALO), Parse Biosciences through its acquisition by Qiagen (NYSE: QGEN), and Forge Biologics through its acquisition by Ajinomoto. As lead investor, he anchored the U.S. market transition for Verona Pharma (Nasdaq: VRNA), culminating in the $10.8B acquisition by Merck, and led the pre-IPO investment in Harmony Biosciences (Nasdaq: HRMY), which scaled WAKIX into a new category in sleep medicine. Dr. Goldberg is among the first physicians in the United States to earn dual board certification in Critical Care Medicine and Emergency Medicine. He served as an Instructor in Medicine at the Mayo Clinic, where he completed a Critical Care fellowship, after training in Emergency Medicine at LAC+USC. He has over 25 scientific publications including research on tobacco advertising, published in JAMA, that examined youth targeting and contributed to public-health initiatives that earned him the Oregon Governor’s Council Outstanding Achievement Award. Dr. Goldberg received his MD from The George Washington University School of Medicine and a post-doctoral diploma in translational science from the Mayo Graduate School.

Erik Atkisson is the Chief Legal Officer at Achieve Life Sciences, bringing over 25 years of experience in the pharmaceutical and biotechnology industries. Mr. Atkisson has deep expertise in guiding the global development, launch, and commercialization of biopharmaceutical products, and has held senior legal positions at multiple clinical- and commercial-stage biopharmaceutical companies. Prior to Achieve, Mr. Atkisson served as General Counsel, Corporate Secretary, and Chief Compliance Officer at Rain Oncology, leading all legal matters including governance, IP, contracting, regulatory, privacy, and litigation. Earlier in his career, Mr. Atkisson served as General Counsel of Eiger BioPharmaceuticals and Chief Compliance Officer of Cytokinetics. He also held senior positions at Amneal Pharmaceuticals (formerly Impax Laboratories) and BioMarin Pharmaceutical. Mr. Atkisson holds a J.D. from Georgetown University Law Center, an M.Sc. from the University of Edinburgh, and a B.A. from Harvard University.

Craig Donnelly is the Chief Operations Officer at Achieve Life Sciences, following his previous position as Achieve’s Executive Vice President, CMC and Regulatory CMC. In this expanded role, Craig will be responsible for optimizing operations efficiency in the company’s manufacturing, supply chain, CMC operations and product life-cycle management, while ensuring the company maintains the highest standards of quality and regulatory compliance. With over 25 years of experience in the biopharmaceutical industry, Craig has expertise in both technical development and regulatory CMC at all stages of development. He formerly held senior roles in CMC and regulatory functions at companies including NuCana, ICON (formerly Mapi), and F. Hoffman-La Roche. He began his career at Pfizer as an analytical chemist before advancing to a project leadership role and served as a Team Leader at Almac Sciences. Craig holds a Bachelor’s with Honors in Chemical and Pharmaceutical Sciences from the University of Sunderland.

Mr. Oki has served as our Chief Financial Officer since December 2024. From January 2022 to November 2024, Mr. Oki served as Chief Financial Officer of Aytu Biopharma, Inc., a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products. From 2015 through January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC (formerly Vivus Inc.), a commercial-stage pharmaceutical company formerly listed on Nasdaq. From 2006 to 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance, Chief Financial Officer and Secretary. Before Alexza, Mr. Oki held roles of increasing responsibility at Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation), both life sciences companies. Mr. Oki began his career in public accounting at Deloitte & Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration – Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).

Dr. Mark L. Rubinstein is the Chief Medical Officer at Achieve Life Sciences, bringing more than two decades of experience in clinical medicine, scientific research and medical affairs leadership, with a strong focus on nicotine cessation and preventive medicine. Prior to joining Achieve, Dr. Rubinstein served as the Head of Medical Affairs at Blip, where he spearheaded the company’s strategy to help smokers and vapers quit through FDA-approved medications and digital support tools. He was also Vice President of Global Scientific Affairs at Juul Labs, where he led efforts to prevent youth usage of nicotine products. He is Professor Emeritus of Pediatrics at the University of California, San Francisco (UCSF), where his NIH-funded research advanced understanding of adolescent nicotine addiction and smoking cessation interventions. Dr. Rubinstein earned his M.D. from Yale School of Medicine, completed his Internal Medicine residency at Yale–New Haven Hospital, and is board certified in Internal Medicine and Adolescent Medicine.

Ms. Jaime Xinos has 25 years of commercial experience in the biotechnology and pharmaceutical industries. She is an inspirational thought leader, highly skilled in translating science into business as well as developing commercial strategies for specialty products across all stages of the product development continuum. Jaime has served as the Chief Commercial Officer at Achieve Life Sciences since October 2024. Prior to this role, she served as the Executive Vice President of Commercial at Achieve since joining in 2017. Prior to Achieve, Ms. Xinos was Vice President, Marketing and Corporate Communications at OncoGenex Pharmaceuticals, an oncology biopharmaceutical company she initially joined as Senior Director, Global Oncology Commercial Development in 2010. Prior to OncoGenex, Ms. Xinos held various commercial roles in marketing, commercial development, and sales at Pfizer, Novartis, and Abbott Laboratories. She holds an undergraduate degree in Communications and a Master of Business Administration (MBA) both from the University of Illinois.